Android app Apple app link

AD/PD 2025: Further evidence for efficacy of TauRx's LMTX, despite lack of true placebo comparator

By Yahoo! Finance   |   1 month ago
AD/PD 2025: Further evidence for efficacy of TauRx's LMTX, despite lack of true placebo comparator

At the AD/PD 2025 conference, TauRx Therapeutics presented new data from the Phase III LUCIDITY trial confirming LMTX efficacy in treating mild cognitive impairment and Alzheimer's. Challenges in placebo-controlled trials due to drug properties were addressed by analyzing data from other Alzheimer's trials.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.